Optimizing Low Versus Standard Energy Selective Laser Trabeculoplasty SLT to Manage Glaucoma and Ocular Hypertension
Led by University of Pittsburgh · Updated on 2026-08-14
790
Participants Needed
29
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness of Selective Laser Trabeculoplasty SLT at low energy compared to standard energy for treating glaucoma and ocular hypertension. The study also aims to determine if repeating low energy SLT once a year can better prevent or delay the need for daily eye drop medications than waiting to repeat standard energy SLT until its effects wear off. This is a Phase 3 randomized trial focusing on treatment optimization for these eye conditions.
Participants initially receive SLT treatment at standard energy, where energy levels are adjusted to produce champagne bubbles as a sign of effectiveness. At 12 months, eligible participants are randomly assigned to receive repeat SLT either annually with low energy or as needed with standard energy. The low energy SLT involves 100 treatment spots delivered at a lower energy level, adjusted as needed to maintain optimal response, while the standard energy SLT uses higher energy levels with similar adjustments. One arm of the initial low energy SLT was discontinued after interim analysis.
Throughout the study, participants undergo regular eye pressure measurements and monitoring up to 48 months. Researchers measure outcomes such as survival without needing additional treatment at 12 and 48 months, average intraocular pressure IOP over time, and incidence of IOP spikes. Participants will attend scheduled visits for assessments and treatment as needed, with the total study duration lasting several years to evaluate long-term effects and safety.
CONDITIONS
Brief Title
Clarifying the Optimal Application of SLT Therapy Trial
Research Team
T
Tony Realini, MD, MPH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Low Energy SLT (Investigational arm)
Standard Energy SLT (Active comparator)
What is it?
Selective Laser Trabeculoplasty (SLT) performed at reduced total energy compared to the standard dosing method, evaluated as a planned regimen for intraocular pressure control in glaucoma or ocular hypertension.
The standard application of Selective Laser Trabeculoplasty using established dosing protocols, also used as the active comparator in the trial for intraocular pressure management.
Role in the trial
Investigational arm; participants are assigned to receive low energy SLT during trial treatment phases.
Active comparator arm; participants are assigned to receive standard energy SLT, reflecting current common practice.
Primary clinical purpose
Reduce intraocular pressure (IOP) in adults with high-risk ocular hypertension or mild-to-moderate primary open-angle glaucoma by applying lower levels of laser energy to the trabecular meshwork.
Lower IOP in adults with the same diagnoses using the standard total-energy delivery, which is broadly established for glaucoma and ocular hypertension management.
How it is given or performed
Laser is delivered at a lower total energy setting per protocol to the drainage angle of the eye. May be repeated annually in assigned arms.
Laser is delivered at a standard (higher) total energy dose to the trabecular meshwork, per established dosing protocols, repeated as per trial arm assignment (as-needed, annual or similar schedule).
Evidence status
Currently under prospective evaluation in this large randomized controlled trial. Published rationale and design papers lay out the biological and clinical reasoning, but mature efficacy results are not yet available.
Widely supported by published evidence to reduce intraocular pressure in glaucoma and ocular hypertension, including multiple high-quality studies and practice guidelines.
Important limitations or unknowns
Efficacy and durability of IOP lowering at reduced energy levels, the need/frequency for annual repetition, and long-term outcome differences are unknown until trial results are available.
Some patients are insufficient responders or may need repeat treatment over time; comparative effects versus reduced energy approach are under ongoing investigation in this and other studies.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Age 18 or older and in good health
Diagnosis in each eye of high-risk ocular hypertension or mild to moderate primary open-angle glaucoma
Best corrected visual acuity (BCVA) of 20/200 or better in each eye
You will not qualify if you...
Use of topical intraocular pressure-lowering medications for more than 6 months in the past 5 years
History of intraocular pressure-lowering laser or surgical procedures (excluding prophylactic iridotomy)
Advanced primary open-angle glaucoma in either eye
Glaucoma types other than primary open-angle glaucoma
Mean intraocular pressure (IOP) over 35 mmHg at screening or baseline
Narrow or closed angle in either eye
Contraindications to SLT or study interventions
Corneal problems preventing accurate IOP measurement
Eye surgery within the past 6 months
Inability to attend all scheduled study visits
Pregnancy or plan to become pregnant within 4 years
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit
Initial SLT Treatment
Duration - Up to 12 months
Participants receive initial SLT treatment at standard energy with energy adjusted to produce champagne bubbles during the procedure.
Regular visits for monitoring and assessment
Randomized Repeat SLT Treatment
Duration - Up to 36 months
At 12 months, eligible participants are randomly assigned to receive repeat SLT either annually at low energy or as needed at standard energy, with energy adjusted during treatment.
Visits scheduled as needed for repeat treatments and assessments
Long-term Monitoring
Duration - Up to 48 months
Participants undergo regular eye pressure measurements and monitoring to assess treatment effectiveness and safety over time.
Periodic visits at 12, 24, 36, and 48 months
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Design and Baseline Characteristics of Participants in the Clarifying the Optimal Application of Selective Laser Trabeculoplasty (SLT) Therapy (COAST) Trial 1.
Tony Realini, Goundappa Balasubramani, Tanya Kenkre...